China SARS vaccine passes first hurdle - state media

	Tweet

Chinese researchers have developed a SARS vaccine that has passed the first stage of human trials, state media reported on Monday, raising hopes for prevention of a virus that killed some 800 people since it emerged in 2002.

Antibodies against the virus that causes severe acute respiratory syndrome developed in 24 of 36 volunteers in the trial, the official Xinhua news agency said, though several more clinical trials were required before the vaccine would be ready for commercial use.

"We have finished our first-phase clinical test in line with international vaccine-testing requirements,” the China Daily quoted the director of the research team, Yin Weidong, as saying.

SARS infected more than 8,000 people in nearly 30 countries and killed nearly 800 following an outbreak that first emerged in southern China in 2002. It briefly re-emerged in China in April, killing one person and fueling fears that the disease could surface in an annual cycle similar to human flu.

The Chinese government was accused of initially covering up the disease, but now more than 100 scientists had joined China’s research program, the China Daily said.

There were more than 10 types of potential SARS vaccines under development, the newspaper said. Four of them, developed in Canada and the United States, would go into clinical trials by the end of the year.

RELATED STORIES:
North Korea working to contain bird flu   Angola at critical stage in Marburg battle   Human damage to earth worsening fast: report   Vietnam nurse infected with bird flu - doctor   Failure to adopt new drugs fuels rise of malaria   West Nile fever more severe than formerly thought   Japan braces for potential radiation catastrophe   TV food advertisements promote imbalanced diets   WHO Calls for Improved Delivery of Health Care in Developing World   Darfur humanitarian crisis seems to have eased - WHO   Malaria funding short, but some get what they need   More hand-washing won’t curb hospital infections

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]